Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2018-002926-22-HU
EUCTR2018-002926-22-HUActive, not recruitingPhase 1

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Helsinn Healthcare SA0 sites316 target enrollmentStarted: February 21, 2019Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
316
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Inclusion Criteria

  • •1. Signed written informed consent
  • •2. Female or male =18 years of age
  • •3. Documented histologic or cytologic diagnosis of American Joint Committee on Cancer (AJCC) Stage III or IV NSCLC. Stage III patient must have unresectable disease
  • •4. Body mass index < 20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening
  • •5. Ongoing problems with appetite/eating associated with the underlying cancer, as determined by having score of = 17 points on the 5-item Anorexia Symptom Scale and = 37 points on the 12-item FAACT A/CS
  • •6. Patient receiving or not receiving systemic anti-cancer treatment at the time of screening are eligible to participate. Systemic anti-cancer treatment includes first, second, third treatment line with chemotherapy/radiation therapy, immunotherapy or targeted therapy.
  • •Patient not receiving systemic anti-cancer treatment is eligible if:
  • •a. Not planning to receive anti-cancer treatment and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle
  • •b. Planning to receive anti-cancer treatment within 14 days from randomization and/or at least 14 days must be elapsed from the completion of prior treatment at the day of screening, in case underwent previous cycle
  • •c. Patient on palliative care treatment
  • •7. ECOG performance status 0,1 or 2 at screening
  • •8. AST (SGOT) and ALT (SGPT) = 3 x ULN or if hepatic metastases are present = 5 x ULN
  • •9. Adequate renal function, defined as creatinine =2 x ULN, or calculated creatinine clearance >30 ml/minute
  • •10. Female patient shall be: a) of non-childbearing potential or
  • •b) of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test within 24 hours prior to first dose of investigational product
  • •11. The patient must be willing and able to comply with the protocol tests and procedures
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 211
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 105

Exclusion Criteria

  • •1. Patient with other forms of lung cancer (e.g., small cell, neuroendocrine tumors)
  • •2. Woman who is pregnant or breast-feeding
  • •3. Reversible causes of reduced food intake, as determined by the Investigator. These causes may include but are not limited to:
  • •a. NCI CTCAE Grade 3 or 4 oral mucositis,
  • •b. NCI CTCAE Grade 3 or 4 GI disorders [nausea, vomiting, diarrhea, and constipation],
  • •c. mechanical obstructions making patient unable to eat,
  • •d. severe depression
  • •4. Patient undergoing major surgery (central venous access placement and tumor biopsies are not considered major surgery) within 4 weeks prior to randomization. Patient must be well recovered from acute effects of surgery prior to screening. Patient should not have plans to undergo major surgical procedures during the treatment period
  • •5.Patient currently taking androgenic compounds including but not limited to testosterone, testosterone-like agents, oxandrolone, Megestrol acetate; Corticosteroids [for details see Section; Olanzapine, mirtazapine (however, long-term use of mirtazapine for depression for at least four weeks prior to screening is allowed); Dronabinol; Marijuana (cannabis) or
  • •Any other prescription medication or off-label products intended to increase appetite or treat unintentional weight loss.
  • •6. Patient with pleural effusion requiring thoracentesis, pericardial effusion requiring drainage, edema or evidence of ascites
  • •7. Patient with uncontrolled or significant cardiovascular disease, including:
  • •a. History of myocardial infarction within the past 3 months
  • •b. A-V block of second or third degree (may be eligible if currently have a pacemaker)
  • •c. Unstable angina
  • •d. Congestive heart failure within the past 3 months, if defined as NYHA class III-IV
  • •e. Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, Wolff-Parkinson-White (WPW) syndrome, or torsade de pointes)
  • •f. Uncontrolled hypertension (blood pressure >150 mm Hg systolic and >95 mm Hg diastolic)
  • •g. Heart rate < 50 beats per minute on pre-entry electrocardiogram and patient is symptomatic
  • •8. Patient on drugs that may prolong the PR or QRS interval durations, such as any of the antiarrhythmic medications Class I (Fast sodium (Na) channel blockers)
  • •9. Patient unable to readily swallow oral tablets
  • •10. Patient with severe gastrointestinal disease (including esophagitis, gastritis, malabsorption)
  • •11. Patient with history of gastrectomy
  • •12. Patient with uncontrolled diabetes mellitus or unmonitored diabetes mellitus
  • •13. Patient with cachexia caused by other reasons, as determined by the investigator such as:
  • •a. Severe COPD requiring use of home O2,
  • •b. New York Heart Association (NYHA) class III-IV heart failure
  • •d. Uncontrolled thyroid disease
  • •14. Patient receiving strong CYP3A4 inhibitors within 14 days of randomization
  • •15. Patient currently receiving tube feedings or parenteral nutrition (either total or pa

Investigators

Similar Trials

Active, not recruiting
Phase 1
A Study in Patients with Chronic Cluster HeadacheChronic Cluster HeadacheMedDRA version: 18.0 Level: LLT Classification code 10009698 Term: Cluster headaches System Organ Class: 100000004852
EUCTR2014-005429-11-FREli Lilly and Company162
Active, not recruiting
Phase 1
A Study in Patients with Chronic Cluster HeadacheChronic Cluster HeadacheMedDRA version: 19.0 Level: LLT Classification code 10009698 Term: Cluster headaches System Organ Class: 100000004852
EUCTR2014-005429-11-GREli Lilly and Company162
Active, not recruiting
Phase 1
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with standard of care in patients with stomach cancer.
EUCTR2015-001526-42-HUGilead Sciences, Inc.430
Active, not recruiting
Not Applicable
Tasquinimod for metastatic castrate-resistant prostate cancerMetastatic Castrate-Resistant Prostate CancerMedDRA version: 14.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10062904Term: Hormone-refractory prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-021870-12-EEActive Biotech AB1,200
Completed
Phase 3
A Phase 3 study of Abatacept in Patients with Primary Sjogrens SyndromePrimary Sjogrens Syndrome
JPRN-jRCT2080223466Bristol-Myers Squibb K.K.172
Study to Evaluate the Efficacy and Safety... | Clinical Trial